Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.4.24.83: anthrax lethal factor endopeptidase

This is an abbreviated version!
For detailed information about anthrax lethal factor endopeptidase, go to the full flat file.

Word Map on EC 3.4.24.83

Reaction

Preferred amino acids around the cleavage site can be denoted BBBBxHx-/-H, in which B denotes Arg or Lys, H denotes a hydrophobic amino acid, and x is any amino acid. The only known protein substrates are mitogen-activated protein (MAP) kinase kinases =

Synonyms

anthrax lethal factor, anthrax lethal factor protease, anthrax lethal toxin, anthrax LF, anthrax toxin lethal factor, Bacillus anthracis lethal toxin, lethal factor, lethal factor of anthrax toxin, lethal toxin, LeTx, LF, LTx

ECTree

     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.24 Metalloendopeptidases
                3.4.24.83 anthrax lethal factor endopeptidase

Inhibitors

Inhibitors on EC 3.4.24.83 - anthrax lethal factor endopeptidase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1E,6E)-4-(1,3-dithian-2-ylidene)-1,7-difuran-2-ylhepta-1,6-diene-3,5-dione
-
-
(1Z,6E)-4-(1,3-dithian-2-ylidene)-1,7-difuran-2-ylhepta-1,6-diene-3,5-dione
-
-
(2R)-2-[(4-fluoro-3-methoxybenzene-1-sulfonyl)(2-methylpropyl)amino]-N-hydroxy-3-methylbutanamide
-
(2R)-2-[(4-fluoro-3-methylbenzene-1-sulfonyl)(2-methylpropyl)amino]-N-hydroxy-3-methylbutanamide
-
(2R)-2-[(4-fluoro-3-methylbenzene-1-sulfonyl)amino]-N-hydroxy-2-(oxan-4-yl)acetamide
(2R)-2-[(4-fluoro-3-methylbenzene-1-sulfonyl)[(4-nitrophenyl)methyl]amino]-N-hydroxypropanamide
-
(2R)-N4-hydroxy-N1-[(2S)-3-(1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl]-2-(2-methylpropyl)butanediamide
-
inhibitor identified by in silico high-throughput virtual screening protocol
(2S)-2-(3,4-dichlorophenyl)-N-hydroxy-3-(3-methylphenyl)propanamide
-
(2S)-2-(4-fluoro-3,5-dimethylbenzyl)-6-[[1-(4-fluorophenyl)propyl]amino]-N-hydroxyhexanamide
i.e. PT-8541
(2S)-2-[(2R)-2-(4-fluorophenyl)-2-methoxyethyl]-6-[[1-(4-fluorophenyl)propyl]amino]-N-hydroxyhexanamide
i.e. PT-8420
(2S)-6-[(1R)-N-1-(4-fluorophenyl)propan]aminoamino-2-(4-fluoro-3,5-dimethylbenzyl)-N-hydroxyhexanamide
inhibitor provides protection against lethal infection when administered as a monotherapy. Two doses (10 mg/kg) administered at 2 h and 8 h after spore infection are sufficient to provide a significant survival benefit in infected mice
(2S)-6-[(4-fluorobenzyl)amino]-2-[(2R)-2-(4-fluorophenyl)-2-methoxyethyl]-N-hydroxyhexanamide
i.e. LFI4
(2S)-6-[N-1-(4-fluorophenyl)propan]amino-2-[(2R)-2-(4-fluorophenyl)-2-methoxyethyl]-N-hydroxyhexanamide
inhibitor provides protection against lethal infection when administered as a monotherapy. Two doses (10 mg/kg) administered at 2 h and 8 h after spore infection are sufficient to provide a significant survival benefit in infected mice
(3S)-N-hydroxy-4-methyl-3-([[(2R)-1-(methylamino)-1-oxo-4-phenylbutan-2-yl]amino]methyl)pentanamide
-
inhibitor identified by in silico high-throughput virtual screening protocol
(4E)-4-[(2,4-dihydroxyphenyl)methylidene]-1,2,5-thiadiazolidin-3-one
-
-
(5E)-5-(1,3-benzothiazol-2-ylimino)-1-(4-sulfophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid
-
-
(5Z)-3-(4-hydroxyphenyl)-5-[[5-(4-nitrophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(4-methoxyphenyl)-2-thioxo-5-([5-[3-(trifluoromethyl)phenyl]furan-2-yl]methylidene)-1,3-thiazolidin-4-one
-
-
(5Z)-3-(furan-2-ylmethyl)-5-[[5-(3-nitrophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(furan-2-ylmethyl)-5-[[5-(4-nitrophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(2,4-dihydroxyphenyl)methylidene]-2-thioxoimidazolidin-4-one
-
-
(5Z)-5-[[5-(2-nitrophenyl)furan-2-yl]methylidene]-3-(2-phenylethyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(4-bromo-3-chlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-3-(furan-2-ylmethyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(4-fluorophenyl)furan-2-yl]methylidene]-3-prop-2-en-1-yl-2-thioxo-1,3-thiazolidin-4-one
-
-
(9E)-N-[2-(2,4,5-trihydroxyphenyl)ethyl]octadec-9-enamide
-
-
(9E)-N-[2-(3,4,5-trihydroxyphenyl)ethyl]octadec-9-enamide
-
-
(9Z)-N-(3,4-dihydroxybenzyl)octadec-9-enamide
-
-
(9Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]octadec-9-enamide
-
-
(D-Arg)9-Trp-Leu-Met-CONHOH
-
(D-Arg)9-Val-Leu-Arg-CONHOH
-
(D-R)9LPY-CO-NHOH
-
-
(D-R)9VLR-CO-NHOH
-
-
(D-R)9WLM-CO-NHOH
-
-
1,4-dihydroxy-10-methoxy-5,8-dimethyl-3,7-dioxo-1,3-dihydro-7H-2,6,12-trioxabenzo[5,6]cyclohepta[1,2-e]indene-11-carbaldehyde
i.e. stictic acid
1-[(1S,2R,3S,4S,6S)-2-amino-6-[(6-amino-2,6-dideoxy-a-D-arabino-hexopyranosyl)oxy]-3,4-dihydroxycyclohexyl]guanidine
-
-
1-[([1,1'-biphenyl]-4-yl)methyl]-3-hydroxy-2-methylpyridine-4(1H)-thione
i.e. 94G5
2-([benzyl(ethyl)amino]methyl)-6-iodo-4-methylphenol
-
inhibitor identified by in silico high-throughput virtual screening protocol
2-chloro-4-(5-[(Z)-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)imino]methyl]furan-2-yl)benzoic acid
-
-
2-chloro-4-(5-[(Z)-[4-oxo-3-(pyridin-3-ylmethyl)-2-thioxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl)benzoic acid
-
-
2-chloro-4-[5-[(Z)-(4-oxo-3-prop-2-en-1-yl-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoic acid
-
-
2-chloro-4-[[(4Z)-4-[[4-(methylsulfanyl)phenyl]methylidene]-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl]sulfamoyl]benzoic acid
-
-
2-chloro-5-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid
-
-
2-chloro-5-[(4Z)-3-methyl-4-[[4-(1-methylethyl)phenyl]methylidene]-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid
-
-
2-chloro-5-[(4Z)-4-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid
-
-
2-chloro-5-[[(4Z)-4-[[4-(methylsulfanyl)phenyl]methylidene]-5-oxo-2-phenylimidazolidin-1-yl]sulfamoyl]benzoic acid
-
-
2-hydroxy-5-(5-[(Z)-[2-imino-4-oxo-3-(1,3-thiazol-2-yl)-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl)benzoic acid
-
-
2-hydroxy-5-[5-[(Z)-[2-imino-3-[imino(methylsulfanyl)methyl]-4-oxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]benzoic acid
-
-
2-thiolacetyl-YPM-amide
-
-
2-[[(2-amino-2-carboxyethyl)sulfanyl]methyl]-5-phenylfuran-3-carboxylic acid
-
-
2-[[benzyl(ethyl)amino]methyl]-4,6-diiodophenol
-
2-[[benzyl(ethyl)amino]methyl]-4-bromophenol
-
2-[[benzyl(ethyl)amino]methyl]-4-chlorophenol
-
3,3'-methanediylbis(6-hydroxybenzoic acid)
-
-
3,4-dihydroxy-N'-[(1Z)-(2-hydroxy-5-nitrophenyl)methylidene]benzohydrazide
-
-
3,5-diphenyl-2,6-bis(sulfanyl)-4H-thiopyran-4-one
-
3-(5-[(Z)-[1-(3-chlorophenyl)-3,5-dioxopyrazolidin-4-ylidene]methyl]furan-2-yl)benzoic acid
-
-
3-(benzyloxy)-1-(3,4-dichlorobenzene-1-sulfonyl)-N-hydroxypyrrolidine-2-carboxamide
-
3-(N-hydroxycarboxamido)-2-isobutylpropanoyl-Trp-methylamide
inhibitor used for structure-based pharmacopore model
3-[(5E)-5-[(3-bromo-4-methoxyphenyl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-[(3-bromo-4-methoxyphenyl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-[[5-(2-nitrophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
3-[(5Z)-5-[[5-(4-nitrophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoic acid
-
-
4-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid
-
-
4-(5-[(Z)-[3-(4-nitrophenyl)-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl)benzoic acid
-
-
4-methyl-N-[(1R)-1-[5-(naphthalen-1-yl)-2-(prop-2-en-1-yl)tetrahydrofuran-3-yl]ethyl]benzenesulfonamide
i.e. SM157, non-competitive inhibition
-
4-phenylaminocarbonylbis-demethoxycurcumin
-
inhibitory potency is comparable with curcumin, while showing improved solubility and stability
4-[(5Z)-5-[[5-(3-nitrophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]butanoic acid
-
-
4-[(5Z)-5-[[5-(4-bromophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]butanoic acid
-
-
4-[5-[(E)-(5-cyano-2-hydroxy-4-methyl-6-oxopyridin-3(6H)-ylidene)methyl]furan-2-yl]benzenesulfonamide
-
-
4-[5-[(Z)-(3-benzyl-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoic acid
-
-
4-[5-[(Z)-[4-oxo-2-thioxo-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]benzoic acid
-
-
4-[[(4-chlorophenyl)carbamoyl]amino]-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide
-
-
5-(4-carboxy-3-chlorophenyl)-2-[(Z)-[(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)imino]methyl]furan-3-carboxylic acid
-
-
5-bromo-2-(5-[(Z)-[1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-1,5-dihydro-4H-pyrazol-4-ylidene]methyl]furan-2-yl)benzoic acid
-
-
5-bromo-2-(5-[(Z)-[1-(3-carboxyphenyl)-5-oxo-3-(trifluoromethyl)-1,5-dihydro-4H-pyrazol-4-ylidene]methyl]uran-2-yl)benzoic acid
-
-
5-chloro-2-[5-[(E)-(1,5-dioxo-6,7,8,9-tetrahydro-5H-[1]benzothieno[3,2-e][1,3]thiazolo[3,2-a]pyrimidin-2(1H)-ylidene)methyl]furan-2-yl]benzoic acid
-
-
5-[4-[(E)-2-[(2R,3R,3'R)-3'-(3,5-dihydroxyphenyl)-6'-hydroxy-2,2'-bis(4-hydroxyphenyl)-2,2',3,3'-tetrahydro-3,4'-bi-1-benzofuran-5-yl]ethenyl]-6-hydroxy-2-(3-hydroxyphenyl)-2,3-dihydro-1-benzofuran-3-yl]benzene-1,3-diol
-
6-S-(3-aminopropyl)-6-thio-beta-D-cyclodextrin
-
-
6-S-(8-aminooctyl)-6-thio-beta-D-cyclodextin
-
-
6-S-[3-(aminomethyl)benzyl]-6-thio-beta-D-cyclodextrin
-
-
6-S-[4-(aminomethyl)benzyl]-6-thio-beta-D-cyclodextrin
-
-
8-[(E)-[[4-(2,3-dihydro-1,3-thiazol-2-ylsulfamoyl)phenyl]imino]methyl]-4H-1,3-benzodioxine-6-carboxylic acid
-
-
acetyl-GYbetaARRRRRRRRVLR-hydroxamate
-
-
AcG-Y-betaA-R-R-R-A-R-R-R-R-V-L-R-4-nitroanilide
-
substrate inhibition
AcM-L-A-R-R-R-P-V-L-P-4-nitroanilide
-
substrate inhibition
AcR-R-R-R-V-L-R-4-methylcoumarin-7-amide
-
substrate inhibition
AcR-R-R-R-V-L-R-4-nitroanilide
-
substrate inhibition
C-terminal dimer of the protective antigen binding domain of anthrax lethal factor
-
-
-
C-terminal trimer of the protective antigen binding domain of anthrax lethal factor
-
-
-
celastrol
-
celastrol, a quinine methide triterpene derived from a plant extract used in herbal medicine, inhibits lethal toxin-induced death of RAW264.7 murine macrophages. Celastrol does not prevent cleavage of mitogen activated protein kinase kinase 1. Celastrol confers almost complete protection when it is added up to 1.5 h after intoxication, indicating that it can rescue cells in the late stages of intoxication. Celastrol inhibits the proteasome-dependent degradation of proteins in RAW264.7 cells. Celastrol blocks stimulation of IL-18 processing, indicating that celastrol acts upstream of inflammasome activation
curcumin
-
inhibits by both decreasing catalytic capacity and increasing substrate affinity
fluvastatin
-
statins attenuate lethal factor action action. statin treatment maintains macrophage cell viability above 60% of untreated control cells even after 9 h of lethal toxin treatment. Statins decrease mitogen-activated protein kinase cleavage
guanidine hydrochloride
-
guanidine isothiocyanate
-
In2LF
i.e. Ac-Gly-Tyr-betaAla-(L-Arg)8-Val-Leu-Arg-CONHOH, competitive inhibitor
mevastatin
-
statins attenuate lethal factor action action. statin treatment maintains macrophage cell viability above 60% of untreated control cells even after 9 h of lethal toxin treatment. Statins decrease mitogen-activated protein kinase cleavage
MKARRKKVYP-NHOH
-
-
N'1,N'4-bis[(1E)-(2-hydroxy-5-methylphenyl)methylidene]benzene-1,4-dicarbohydrazide
-
-
N'1-[(1E)-(2-hydroxyphenyl)methylidene]-N'4-[(1Z)-(2-hydroxyphenyl)methylidene]benzene-1,4-dicarbohydrazide
-
-
N'1-[(1E)-(5-fluoro-2-hydroxyphenyl)methylidene]-N'4-[(1Z)-(5-fluoro-2-hydroxyphenyl)methylidene]benzene-1,4-dicarbohydrazide
-
-
N,N''',N'''''',N'''''''''-[[(1R,3S,4S,6R)-4,6-dicarbamimidamidocyclohexane-1,3-diyl]bis(oxybenzene-1,2,4-triyl)]tetraguanidine
-
-
N,N'''-[(1R,3S)-4-(2,4-dicarbamimidamidonaphthalen-1-yl)-6-hydroxycyclohexane-1,3-diyl]diguanidine
-
-
N,N'''-[(1R,3S)-4-(2-amino-1H-benzimidazol-7-yl)-6-hydroxycyclohexane-1,3-diyl]diguanidine
-
-
N,N'''-[(1R,3S,4R,5R,6S)-4-[(2,6-dicarbamimidamido-2,6-dideoxy-a-D-glucopyranosyl)oxy]-5,6-dihydroxycyclohexane-1,3-diyl]diguanidine
-
-
N,N'''-[(1R,3S,4R,6R)-4-(2-carbamimidamidophenyl)-6-hydroxycyclohexane-1,3-diyl]diguanidine
-
-
N,N'''-[(1R,3S,4R,6R)-4-(4-carbamimidamidonaphthalen-1-yl)-6-hydroxycyclohexane-1,3-diyl]diguanidine
-
-
N,N'''-[(1R,3S,4R,6R)-4-(4-carbamimidamidophenyl)-6-hydroxycyclohexane-1,3-diyl]diguanidine
-
-
N,N'''-[(1R,3S,4S,6R)-4-(3-carbamimidamidopyridin-2-yl)-6-hydroxycyclohexane-1,3-diyl]diguanidine
-
-
N,N'''-[(1R,3S,4S,6R)-4-(5-carbamimidamidopyridin-2-yl)-6-hydroxycyclohexane-1,3-diyl]diguanidine
-
-
N,N'''-[(1S,2R,3S,4S,6S)-6-[(6-amino-2-carbamimidamido-2,6-dideoxy-a-D-glucopyranosyl)oxy]-3,4-dihydroxycyclohexane-1,2-diyl]diguanidine
-
-
N,N'''-[4-[(1R,2S,4R,5R)-2,4-dicarbamimidamido-5-hydroxycyclohexyl]benzene-1,3-diyl]diguanidine
-
-
N,N'-bis(4-amino-2-methylquinolin-6-yl)urea
i.e. NSC12155, competitive inhibition
N-(4-amino-2-methylquinolin-6-yl)-3-(2-methoxyphenyl)propanamide
-
N-(4-amino-2-methylquinolin-6-yl)-4-(quinolin-6-yl)benzamide
-
N-2-benzyl-N-2-[(4-fluoro-3-methylphenyl)sulfonyl]-N-hydroxy-D-alaninamide
-
N-2-[4-(aminomethyl)benzyl]-N-2-[(4-fluoro-3-methylphenyl)sulfonyl]-N-hydroxy-D-alaninamide
-
N-hydroxy-4-[2-[(9E)-octadec-9-enoylamino]ethyl]benzamide
-
-
N-hydroxy-4-[[(9Z)-octadec-9-enoylamino]methyl]benzamide
-
-
N-hydroxy-N2-[[3-(methoxymethyl)phenyl]sulfonyl]-N2-(2-methylpropyl)-D-valinamide
-
N-oleoyldopamine
-
uncompetitive inhibition
N-terminal dimer of the protective antigen binding domain of anthrax lethal factor
-
-
-
N-terminal trimer of the protective antigen binding domain of anthrax lethal factor
-
-
-
N-[([1,1'-biphenyl]-4-yl)methyl]-3-hydroxy-4-sulfanylidene-4H-pyran-2-carbothioamide
-
N-[([1,1'-biphenyl]-4-yl)methyl]-3-hydroxy-6-methyl-4-sulfanylidene-4H-pyran-2-carboxamide
i.e. AM-2S
N-[3-(1,3-benzothiazol-2-yl)-4-methylthiophen-2-yl]-4-chlorobenzene-1-sulfonamide
-
N-[3-(1,3-benzothiazol-2-yl)thiophen-2-yl]-4'-methoxy[1,1'-biphenyl]-4-sulfonamide
-
N2-[(4-fluoro-3-methylphenyl)sulfonyl]-N-hydroxy-N-2-(4-nitrobenzyl)-D-alaninamide
-
neamine
-
mixed-type, noncompetitive inhibition
neomycin B
NH4Cl
-
blocks mitogen-activated protein kinase kinase 3 proteolysis in anthrax lethal toxin-treated macrophages
simvastatin
-
statins attenuate lethal factor action action. statin treatment maintains macrophage cell viability above 60% of untreated control cells even after 9 h of lethal toxin treatment. Statins decrease mitogen-activated protein kinase cleavage
verapamil
-
blocks mitogen-activated protein kinase kinase 3 proteolysis in anthrax lethal toxin-treated macrophages
[(5Z)-5-([5-[2-chloro-5-(trifluoromethyl)phenyl]furan-2-yl]methylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[[5-(2-nitrophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[[5-(3-chloro-4-methoxyphenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[[5-(3-chloro-4-sulfamoylphenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[[5-(3-nitrophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[[5-(4-bromophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[[5-(4-chloro-2-nitrophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[(5Z)-5-[[5-(4-iodophenyl)furan-2-yl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
-
[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]acetic acid
-
-
[4-[(5Z)-5-(furan-2-ylmethylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]phenyl]acetic acid
-
-
[[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]sulfanyl]acetic acid
-
-
additional information
-